Black Diamond director awarded 40,000 stock options

Black Diamond Therapeutics director Garry E. Menzel received a stock option award for 40,000 shares of common stock.

Rhea-AI Filing Summary

Black Diamond Therapeutics director Garry E. Menzel received a stock option award for 40,000 shares of common stock. The option has an exercise price of $1.71 per share and expires on June 25, 2036. It was granted as a compensation award rather than a market purchase or sale.

The option will vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, subject to his continued service through that date. Following this grant, he holds 40,000 option-based rights directly.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Menzel Garry E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Option grant size: 40,000 shares Exercise price: $1.71 per share Expiration date: June 25, 2036 +2 more

5 metrics

Option grant size 40,000 shares Underlying common stock in new option award

Exercise price $1.71 per share Stock option strike price

Expiration date June 25, 2036 Option term end date

Post-transaction options held 40,000 options Total derivative securities following award

Vesting schedule Earlier of June 26, 2027 or next annual meeting Full vesting trigger, subject to continued service

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.7100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-25T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service"

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable in full"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Garry E. Menzel report in his Form 4 for Black Diamond Therapeutics (BDTX)?

Garry E. Menzel reported receiving a stock option award for 40,000 shares of Black Diamond Therapeutics common stock. The option was granted as compensation, not through an open-market transaction, and gives him the right to buy shares at a fixed exercise price.

What are the key terms of Garry Menzel’s new BDTX stock option grant?

The stock option covers 40,000 underlying shares of Black Diamond Therapeutics common stock at an exercise price of $1.71 per share. It expires on June 25, 2036 and represents a compensation-related award rather than an immediate purchase or sale of stock.

When will Garry Menzel’s BDTX stock options vest and become exercisable?

The 40,000-share option will vest and become fully exercisable on the earlier of June 26, 2027 or Black Diamond Therapeutics’ next annual meeting of stockholders. Vesting requires Menzel’s continued service with the company through the applicable vesting date described in the award terms.

Does the Form 4 for BDTX show Garry Menzel buying or selling common shares?

The Form 4 does not show Garry Menzel buying or selling common shares in the market. Instead, it reports a grant of a stock option derivative security, giving him the right to acquire 40,000 shares at $1.71 if and when the option vests.

How many BDTX option-based rights does Garry Menzel hold after this transaction?

After this transaction, Garry Menzel holds 40,000 option-based rights directly in Black Diamond Therapeutics. These options are subject to future vesting and provide potential future ownership, rather than reflecting currently owned common shares acquired in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:37 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menzel Garry E

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

245 FIRST STREET, 18TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.71	06/26/2026		A		40,000		(1)	06/25/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)